Literature DB >> 27176678

Newer oral and noninsulin therapies to treat type 2 diabetes mellitus.

Kathie L Hermayer1,2, Andrew Dake3.   

Abstract

The pathophysiology of type 2 diabetes mellitus involves several biologic mechanisms and no single medication addresses them all. Most patients require more than one medication to adequately treat their diabetes, needing drugs with unique and complementary mechanisms of action to address and balance insulin and glucagon levels. In the past decade, several therapeutic drug classes have been developed for type 2 diabetes mellitus. Each provides therapeutic options with novel mechanisms of action to help clinicians achieve the goal of glucose homeostasis while controlling adverse events, especially reducing the risk of hypoglycemia.
Copyright © 2016 Cleveland Clinic.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27176678     DOI: 10.3949/ccjm.83.s1.04

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  3 in total

1.  Adverse Drug Events Associated with sitagliptin Versus canagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Comparison Through a Meta-Analysis.

Authors:  Pravesh Kumar Bundhun; Feng Huang
Journal:  Diabetes Ther       Date:  2018-08-09       Impact factor: 2.945

Review 2.  Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases.

Authors:  Xolani H Makhoba; Claudio Viegas; Rebamang A Mosa; Flávia P D Viegas; Ofentse J Pooe
Journal:  Drug Des Devel Ther       Date:  2020-08-11       Impact factor: 4.162

3.  Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study.

Authors:  Xuejun Victor Peng; Rajeev Ayyagari; Robert Lubwama; Lizheng Shi; Eboni G Price-Haywood; Priscilla Hollander; Vivian Fonseca
Journal:  Diabetes Ther       Date:  2020-02-28       Impact factor: 2.945

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.